Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Diabetes vaccine to start Phase III trials in Europe

Diamyd Medical : 20 March, 2008  (New Product)
The Swedish Medical Products Agency (MPA) has approved the Diamyd Medical 's application to commence Phase III studies with the therapeutic diabetes vaccine Diamyd.
'I am extremely glad that we now can offer our recently diagnosed type 1 diabetes patients the possibility to participate also in the European study,' said professor Johnny Ludvigsson, Linkoping, Sweden, principal investigator for the study.

Diabetes teams from approximately 20 Swedish paediatric clinics will meet in Linkoping, Sweden on April 4, 2008 to go through details for the study, which will comprise 306 new onset type 1 diabetes patients. Diamyd Medical is planning to file clinical trial applications in another three to four European countries and include additionally 20 clinics in the study.

'The approval from the Swedish MPA is another important step in the development of Diamyd towards the market,' said Elisabeth Lindner, president and chief executive officer of Diamyd Medical. 'Last week we received authorisation from the FDA to start a parallel Phase III trial in the USA, and together with TrialNet's planned study in the US, the interest in Diamyd is strong. We receive daily inquiries from parents of patients wanting to participate in our studies.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo